Clinical observation of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma
#3095
Introduction: Clinical observation of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma.
Aim(s): To analyse the efficacy and safety of PD-1 inhibitor combined with anlotinib in the treatment of advanced neuroendocrine carcinoma.
Materials and methods: From January 2018 to June 2020, the data of 45 patients with advanced neuroendocrine carcinoma who had failed first-line standard chemotherapy and were treated with PD-1 inhibitor combined with anlotinib were collected from the First Affiliated Hospital of Zhengzhou University.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author:
Keywords: immune checkpoint inhibitor, anlotinib, neuroendocrine carcinoma,
To read the full abstract, please log into your ENETS Member account.